ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
6,025.17
0.96%
US Tech 100
21,458.00
0.90%
Dow Jones
42,581.78
0.89%
Brent Oil
68.66
-1.70%
Bitcoin
105,149.53
-0.32%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Coya Therapeutics Inc (COYA) Quote

Coya Therapeutics Inc

Coya Therapeutics Inc (COYA)

NASDAQ
5.795
0.29
(5.27%)
Closed June 23 4:00PM
15 min delayed - Upgrade to Realtime
5.795
0.00
( 0.00% )
Pre Market: 7:00AM
15 min delayed - Upgrade to Realtime

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
5.795
Bid
5.80
Ask
6.00
Volume
10
0.00 Day's Range 0.00
4.65 52 Week Range 10.24
Market Cap
96.921M
Previous Close
5.795
Open
-
Last Trade
10
@
5.8
Last Trade Time
07:10:51
Financial Volume
-
VWAP
-
Average Volume (3m)
58,549
Shares Outstanding
16,724,998
Dividend Yield
-
PE Ratio
-6.51
Earnings Per Share (EPS)
-0.89
Revenue
3.55M
Net Profit
-14.88M

About Coya Therapeutics Inc

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-de... Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.coyatherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Coya Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker COYA. The last closing price for Coya Therapeutics was $5.80. Over the last year, Coya Therapeutics shares have traded in a share price range of $ 4.65 to $ 10.24.

Coya Therapeutics currently has 16,724,998 shares outstanding. The market capitalization of Coya Therapeutics is $96.92 million. Coya Therapeutics has a price to earnings ratio (PE ratio) of -6.51.

Ask ADVFN Intelligence (AI)

COYA Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
May 13 2025
COYA (5.27%)

Form 8-K - Current report
Edgar (US Regulatory)
May 13 2025
COYA (5.27%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2955.363636363645.55.875.3550245.62309441CS
4-0.195-3.255425709525.996.035.235463595.56486666CS
12-0.715-10.98310291866.517.054.65585495.76031383CS
260.4859.133709981175.318.294.65742846.21084708CS
52-0.235-3.897180762856.0310.244.65703436.54670811CS
1561.045224.7510.68993.21693686.40529004CS
2601.045224.7510.68993.21693686.40529004CS

COYA - Frequently Asked Questions (FAQ)

What is the current Coya Therapeutics share price?
The current share price of Coya Therapeutics is $ 5.795
How many Coya Therapeutics shares are in issue?
Coya Therapeutics has 16,724,998 shares in issue
What is the market cap of Coya Therapeutics?
The market capitalisation of Coya Therapeutics is USD 96.92M
What is the 1 year trading range for Coya Therapeutics share price?
Coya Therapeutics has traded in the range of $ 4.65 to $ 10.24 during the past year
What is the PE ratio of Coya Therapeutics?
The price to earnings ratio of Coya Therapeutics is -6.51
What is the cash to sales ratio of Coya Therapeutics?
The cash to sales ratio of Coya Therapeutics is 27.25
What is the reporting currency for Coya Therapeutics?
Coya Therapeutics reports financial results in USD
What is the latest annual turnover for Coya Therapeutics?
The latest annual turnover of Coya Therapeutics is USD 3.55M
What is the latest annual profit for Coya Therapeutics?
The latest annual profit of Coya Therapeutics is USD -14.88M
What is the registered address of Coya Therapeutics?
The registered address for Coya Therapeutics is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Coya Therapeutics website address?
The website address for Coya Therapeutics is www.coyatherapeutics.com
Which industry sector does Coya Therapeutics operate in?
Coya Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NANano Labs Ltd
$ 19.22
(76.49%)
1.38M
INMInMed Pharmaceuticals Inc
$ 4.23
(72.65%)
2.74M
IBIOiBio Inc
$ 1.12
(57.22%)
22.5M
KZIAKazia Therapeutics Ltd
$ 10.00
(47.71%)
169
CBIOCrescent Biopharma Inc
$ 20.99
(37.19%)
379
UPXIUpexi Inc
$ 3.73
(-62.70%)
251.61k
MAASMaase Inc
$ 5.30
(-46.63%)
106.48k
HYFMHydrofarm Holdings Group Inc
$ 2.55
(-34.45%)
29
DFDVDeFi Development Corporation
$ 18.38
(-25.92%)
280.79k
RBNERobin Energy Ltd
$ 4.99
(-25.52%)
339.6k
ADILAdial Pharmaceuticals Inc
$ 0.2878
(9.43%)
42.79M
PSTVPlus Therapeutics Inc
$ 0.2223
(20.62%)
42.35M
IBIOiBio Inc
$ 1.12
(57.22%)
22.5M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 14.94
(3.82%)
12.45M
GIBOGIBO Holdings Ltd
$ 0.6806
(20.25%)
11.7M

COYA Discussion

View Posts
FooBarAndGrill FooBarAndGrill 2 weeks ago
Business updates:
Patent protection:
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya”) today announced the issuance of a U.S. patent relevant to its investigational ready-to-use (RTU) liquid formulation of IL-2. In particular, the U.S. Patent and Trademark Office (USPTO) has granted patent number US 12,312,389 B2, which covers methods of producing highly stable liquid formulations of IL-2 (aldesleukin).

IND Date:
Coya is on track and plans to submit the IND for COYA 302 (a proprietary combination of the low dose-rhIL-2 + CTLA4-Ig) by the end of June supporting the initiation of the Phase 2b study in patients with ALS
https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Announces-Issuance-of-New-U-S--Patent-Protecting-Methods-of-Producing-Recombinant-Human-rh-Interleukin-2-aldesleukin-Liquid-Formulations/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 1 month ago
Language I've been waiting for:
"we anticipate is on track for an FDA IND submission in ALS during 2Q 2025 followed by the initiation of a controlled Phase 2 clinical trial."
https://www.sec.gov/Archives/edgar/data/1835022/000095017025069819/coya-ex99_1.htm
👍️0
FooBarAndGrill FooBarAndGrill 3 months ago
Principal Investigator Alireza Faridar, M.D. to provide overview of data for the investigator-initiated “Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer’s disease”

This Calendar

This Session:
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
I've been on the sidelines here.
$COYA has yet to announce a successful IND filing.
They have not even disclosed what additional information is required. On July 12, 2024, the Company received an email notification from the FDA stating that additional non-clinical data is required prior to the initiation of the Study. The FDA also stated that it would provide the Company with more details about what additional information it requires within the next thirty (30) days. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524178809/d762748d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
ALS drug failures and why COYA 302 is different
https://www.digitaljournal.com/tech-science/als-drug-failures-and-why-coya-302-is-different/article
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
Coya Therapeutics (COYA): BTIG Buy $15 PT March 2nd, 2025
https://coyatherapeutics.wordpress.com/2025/03/02/coya-therapeutics-coya-btig-buy-15-pt-march-2nd-2025/
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
Coya reports good results.
https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Reports-Statistically-Significant-Improvement-of-Inflammatory-Blood-Markers-in-Patients-with-Alzheimers-Disease-Following-Monthly-Dosing-with-Low-Dose-IL-2-Further-Supporting-Clinical-Development/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
Coya announces the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory diseases.
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/95283171/coya-therapeutics-announces-pipeline-expansion-c
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
Dec 18, 2024
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Provides-Enrollment-Update-of-the-Investigator-Initiated-Phase-1-Study-of-Low-Dose-Interleukin-2-LD-IL-2--CTLA4-Ig-Fusion-Protein-in-Patients-with-Frontotemporal-Dementia-FTD/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
Worth a listen:
https://wsw.com/webcast/evercore44/register.aspx?conf=evercore44&page=coya&url=https://wsw.com/webcast/evercore44/coya/2360484
👍️0
FooBarAndGrill FooBarAndGrill 7 months ago
Q&A with Coya's new CEO.
https://houston.innovationmap.com/coya-therapeutics-arun-swaminathan-ceo-2670009696.html
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Web/Con Tuesday, October 29, at 8am ET
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=xpdYyUGI
or Dial: 1-866-807-9684
https://www.businesswire.com/news/home/20241028411053/en/
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Two events next week in Madrid (ADDF followed by CTAD)
Agenda ADDF Summit 2024 COYA presenting.
https://summit.alzdiscovery.org/agenda
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Clinical Trials Results Poster P027 by Stanley Appel CTAD 2024
https://www.ctad-alzheimer.com/files/files/PROGRAM_CTAD2024_WEB%20OCTOBER%2018.pdf
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
1,379,314 shares Private placement @$7.25
8K https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524240775/d877895d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Positive piece from H.C.Wainwright
https://coyatherapeutics.wordpress.com/2024/09/16/coya-therapeutics-coya-h-c-wainwright-buy-18-pt-engaging-immunomudulation-in-nuerology/
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Positive piece published by Seeking Alpha
https://seekingalpha.com/article/4726428-coya-therapeutics-several-near-term-share-price-appreciation-catalysts
👍️0
FooBarAndGrill FooBarAndGrill 9 months ago
Coya announces that CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will participate in a fireside chat at the Chardan 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:00pm ET.
👍️0
Monksdream Monksdream 10 months ago
COYA under $7

👍️0
FooBarAndGrill FooBarAndGrill 10 months ago
Rarely do I see pre-market volume. 2K so far today. Nice.
👍️0
FooBarAndGrill FooBarAndGrill 10 months ago
Officers come and go. On August 19, 2024, Coya Therapeutics, Inc. (the “Company”) announced a planned change in management. Effective November 1, 2024, Arun Swaminathan, the Company’s Chief Business Officer since April 2023, will serve as Chief Executive Officer of the Company. Dr. Swaminathan will succeed Dr. Howard Berman, who, on August 16, 2024, notified the Company that he would be resigning as Chief Executive Officer of the Company effective at the close of business on October 31, 2024. After his resignation, Dr. Berman intends to remain a member of the Company’s board of directors (the “Board”) and serve as Executive Chairman of the Board. Upon his resignation, the Company anticipates that it will enter a consulting agreement with Dr. Berman, with an expected term of 12 months, pursuant to which Dr. Berman will provide consulting services to the Company.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524202551/d861081d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 11 months ago
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Expands-Pipeline-and-Intellectual-Property-Portfolio-with-Filing-of-New-U.S.-Patents-for-COYA-301-in-Combination-with-Glucagon-Like-Peptide-1-GLP-1-Receptor-Agonists/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 11 months ago
COYA to present AD results at CTAD24
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-that-Results-from-a-Double-Blind-Placebo-Controlled-Study-in-Alzheimers-Disease-will-be-presented-on-October-29-2024-at-the-Clinical-Trials-on-Alzheimers-Disease-Conference-CTAD24-in-Madrid/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 11 months ago
Coya 8K July 15
On June 14, 2024, Coya Therapeutics, Inc. (the “Company”) submitted to the U.S. Food and Drug Administration (the “FDA”) an Investigational New Drug Application (the “IND”) seeking to initiate a study entitled “Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Open Label Extension (OLE) to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)” (the “Study”). On July 12, 2024, the Company received an email notification from the FDA stating that additional non-clinical data is required prior to the initiation of the Study. The FDA also stated that it would provide the Company with more details about what additional information it requires within the next thirty (30) days.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524178809/d762748d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
The WOW signal!
Prior to initiating treatment, patients were declining at an average rate of -1.1 points per month on the ALSFRS-R rating scale- At the end of 6 months of treatment, the mean rate of change on the ALSFRS-R was +0.04 points per month.
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
$COYA ALS Peer-Reviewed Publication:
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1415106/full
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology. A portion of the data from the manuscript was previously presented at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference.
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93970259/coya-therapeutics-announces-acceptance-of-peer-rev
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Today 2 Jun is #LouGehrigDay #EndALS
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
It’s T+1 time
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
On May 17, 2024, Coya Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Alzheimer’s Drug Discovery Foundation (the “ADDF”) for the issuance and sale in a private placement (the “Private Placement”) of 603,136 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $8.29 per share for gross proceeds to the Company of $5.0 million.
ADDF >>>> https://www.alzdiscovery.org/
8K >>>>>>> https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524142950/d820823d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Validating A Better ALS Biomarker With Coya's Fred Grossman
Fred discusses $COYA's 1H2024 plans for a IND application and the 2H2024 P2 trial.
https://www.clinicalleader.com/doc/validating-a-better-als-biomarker-with-coya-s-fred-grossman-0001
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-to-Participate-in-the-3rd-Annual-ALS-Drug-Development-Summit/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
And in the world of ALS.
Amylyx Pharmaceuticals said it would voluntarily remove its drug for amyotrophic lateral sclerosis from the market, a rare move that comes less than a month after a clinical trial showed its once-promising treatment for the fatal disease doesn’t work.
https://www.washingtonpost.com/business/2024/04/04/amylyx-als-drug/
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Investing in the fight against ALS. Hosted by Schwab Network.
https://schwabnetwork.com/video/investing-in-the-fight-against-als
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
COYA 2023 10-K
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000095017024033161/coya-20231231.htm
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000095017024033159/coya-20240319.htm
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Neuroimmune Pharmacology Conference Powerpoint
https://s201.q4cdn.com/307844724/files/doc_news/2024/NeuroimmunePharmacology3-12-2024-4.pdf
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Dr. Stan Appel will be presenting during a 30-minute segment at the The 28th Society of Neuroimmune Pharmacology Conference.
March 10-13, 2024 The Francis Marion Hotel, Charleston
https://s-nip.org/documents/2024/SNIP_2024_Schedule.pdf
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Empowering Patient Story and Coya’s Fight Against Neurodegenerative Diseases
Coya’s VP of Operations and Patient Advocacy, Daniel Barvin, had the opportunity to shed light on the world of his empowering patient story and Coya’s fight against neurodegenerative diseases in Houston for the Reel Abilities, UP Abilities event.
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
21 Feb: COYA letter to stockholders.
Today, we announce that we are further expanding the pipeline for COYA 302, adding Alzheimer’s disease (AD) to its growing list of indications
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93327358/coya-therapeutics-issues-letter-to-stockholders-hi
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
About ALS:
ALS is a progressive disease, meaning the symptoms get worse over time. The functional status of ALS patients declines about 1 point per month on average, as measured by the Revised ALS Function Rating Scale1, or ALSFRS-R, a validated tool to monitor the progression of the disease.

COYA results:
Patients' disease progression was measured using the ALSFRS-R scale. The mean scores after initiation of treatment were not statistically different compared to the score at baseline, suggesting significant amelioration in the progression of the disease over the 48-week treatment period.

https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93265319/coya-therapeutics-licenses-intellectual-property-r
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
SEC Form 4's
$COYA announced small option grants (5000 shr @ $7.41) for 3 BOD members. I expect more announcements to come.
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
8K 19 Jan 2024
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524010775/d732822d8k.htm
As of December 31, 2023, Coya Therapeutics, Inc. (the “Company”) had cash and cash equivalents (unaudited) of $32.6 million. In January 2024, the Company received $7.5 million from Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”), as required under the terms of the Development and License Agreement entered into with Dr. Reddy’s on December 5, 2023, which was previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023 (the “Form 8-K”).

The Company’s cash and cash equivalents as of December 31, 2023, pro forma for receipt of the $7.5 million from Dr. Reddy’s (as if such amount was received on December 31, 2023) would be $40.1 million.

In addition, as previously disclosed in the Form 8-K, (i) upon the first Food and Drug Administration (FDA) acceptance of an investigational new drug (IND) application for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS), Dr. Reddy’s will pay the Company an additional $4.2 million, and (ii) upon dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States, Dr. Reddy’s will pay the Company an additional $4.2 million.

The Company anticipates that the IND filing will be made in the first half of 2024 and the dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States will occur in the second half of 2024.

The Company expects its cash and cash equivalents described above will be sufficient to meet its operating needs into 2026.
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
$COYA current shares in issue: 10M
A Private placement announced DEC 5 2023 added 4.4M shares + 319K warrants.
Prospectus announced today will allow those shares to trade. The 319K warrants may also be exercised.
Currently most shares are held tightly.
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
I'm not much of a predictor. And most of the shares are tightly held.
But the company does have my respect and a good outlook long term.
👍️0
Sirpeter Sirpeter 1 year ago
Where do you see the PPS heading by year end
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Coya has a clear path towards submission of the IND application to the FDA in the second quarter of 2024, with a planned initiation of a well-controlled, double-blind clinical trial of COYA 302 in patients with ALS upon acceptance of the IND
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Scientists solve 18-year-old mystery and find the once-elusive source of a critical T cell population
https://medicalxpress.com/news/2023-12-scientists-year-old-mystery-once-elusive-source.html
👍️0
FooBarAndGrill FooBarAndGrill 2 years ago
2023, $COYA has secured a private placement agreement plus a partnership agreement with $RDY. These two deals will provide non-dilutive financing thru 2026.
👍️0
FooBarAndGrill FooBarAndGrill 2 years ago
T-Cells are a focus of COYA research. Understanding the language is helpful.
CAR-T cells are Chimeric Antigen Receptors. (T-Cells)
Tregs are Regulatory T-Cells.
T-Cells have great potential.
‘It’s all gone’: CAR-T therapy forces autoimmune diseases into remission
👍️0

Your Recent History

NASDAQ
COYA
Coya Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads